Inmune Bio, Inc. SEC filings INMB
Inmune Bio, Inc. has 601 filings in SEC EDGAR's recent list, going back to Jul 13, 2017. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (material agreement, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-A12B/A | Amendment no. 5 to form 8-a12b | Dec 8, 2025 | — |
| DEFR14A | Revised definitive proxy statement | May 9, 2025 | — |
| 8-A12B/A | Amendment no. 4 to form 8-a12b | Dec 9, 2024 | — |
| EFFECT | Filing | Aug 7, 2024 | — |
| CORRESP | Letter to the SEC | Aug 5, 2024 | — |
| CORRESP | Letter to the SEC | Aug 1, 2024 | — |
| CORRESP | Letter to the SEC | Jul 30, 2024 | — |
| UPLOAD | Letter from the SEC | May 3, 2024 | — |
| 8-A12B/A | Amendment no. 3 to form 8-a12b | Dec 18, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 10, 2023 | — |
| CORRESP | Letter to the SEC | Mar 31, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 28, 2023 | — |
| 8-A12B/A | Amendment no. 2 to form 8-a12b | Dec 12, 2022 | — |
| 8-A12B/A | Amendment no. 1 to form 8-a12b | Dec 21, 2021 | — |
| EFFECT | Filing | Sep 17, 2021 | — |
| CORRESP | Letter to the SEC | Sep 15, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 13, 2021 | — |
| EFFECT | Filing | May 5, 2021 | — |
| EFFECT | Filing | May 5, 2021 | — |
| CORRESP | Letter to the SEC | May 3, 2021 | — |
| CORRESP | Letter to the SEC | May 3, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 20, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 18, 2021 | — |
| 8-A12B | For registration of certain classes | Dec 30, 2020 | — |
| EFFECT | Filing | Apr 20, 2020 | — |
| EFFECT | Filing | Apr 2, 2020 | — |
| CORRESP | Letter to the SEC | Mar 31, 2020 | — |
| UPLOAD | Letter from the SEC | Mar 31, 2020 | — |
| EFFECT | Filing | Jul 26, 2019 | — |
| CORRESP | Letter to the SEC | Jul 24, 2019 | — |
| UPLOAD | Letter from the SEC | Jul 24, 2019 | — |
| EFFECT | Filing | Jul 2, 2019 | — |
| CORRESP | Letter to the SEC | Jun 27, 2019 | — |
| UPLOAD | Letter from the SEC | Jun 27, 2019 | — |
| D | Filing | May 10, 2019 | — |
| CERT | Filing | Feb 1, 2019 | — |
| 8-A12B | Form 8-a12b | Feb 1, 2019 | — |
| EFFECT | Filing | Dec 19, 2018 | — |
| CORRESP | Letter to the SEC | Dec 17, 2018 | — |
| CORRESP | Letter to the SEC | Dec 17, 2018 | — |
| CORRESP | Letter to the SEC | Nov 30, 2018 | — |
| UPLOAD | Letter from the SEC | Nov 6, 2018 | — |
| CORRESP | Letter to the SEC | Oct 29, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 5, 2018 | — |
| UPLOAD | Letter from the SEC | Sep 17, 2018 | — |
| CORRESP | Letter to the SEC | Aug 30, 2018 | — |
| UPLOAD | Letter from the SEC | Jul 17, 2018 | — |
| DRS/A | Filing | Jun 13, 2018 | — |
| DRSLTR | Filing | Jun 12, 2018 | — |
| UPLOAD | Letter from the SEC | Mar 5, 2018 | — |
| DRS/A | Filing | Feb 14, 2018 | — |
| DRSLTR | Filing | Feb 13, 2018 | — |
| UPLOAD | Letter from the SEC | Jan 3, 2018 | — |
| DRS | Filing | Dec 1, 2017 | — |
| DRSLTR | Filing | Nov 30, 2017 | — |
| D | Filing | Jul 13, 2017 | — |
Showing 56 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INMB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Boca Raton, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1711754
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.